![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PEREGRINE AND NABTT CONSORTIUM INITIATE BRAIN CANCER TRIAL
PEREGRINE AND NABTT CONSORTIUM INITIATE BRAIN CANCER TRIAL
August 29, 2005
Peregrine Pharmaceuticals and the New Approaches to Brain Tumor Therapy (NABTT) Consortium have initiated a clinical trial designed to confirm the dosing, safety and efficacy of a single intratumoral infusion of Cotara in the treatment of glioblastoma multiforme, a common and deadly form of brain cancer.
The National Cancer Institute-approved protocol titled, "An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B (Cotara) for the Treatment of Glioblastoma Multiforme at 1st or 2nd Relapse," will evaluate safety, radiation exposure and efficacy of a single dose of Cotara. The study represents the first part of Peregrine's FDA-approved product registration clinical trial for Cotara.
The trial will enroll patients at four NABTT institutions: Wake Forest University, Emory University, University of Alabama at Birmingham and University of Pennsylvania. Up to 28 patients will be enrolled in the trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct